Wall Street analysts expect HTG Molecular Diagnostics Inc (NASDAQ:HTGM) to report earnings per share (EPS) of ($0.17) for the current quarter, Zacks reports. Two analysts have issued estimates for HTG Molecular Diagnostics’ earnings. The lowest EPS estimate is ($0.24) and the highest is ($0.09). HTG Molecular Diagnostics posted earnings per share of ($0.22) during the same quarter last year, which indicates a positive year-over-year growth rate of 22.7%. The business is scheduled to issue its next earnings results on Thursday, May 9th.
According to Zacks, analysts expect that HTG Molecular Diagnostics will report full-year earnings of ($0.56) per share for the current fiscal year, with EPS estimates ranging from ($0.60) to ($0.49). For the next financial year, analysts forecast that the company will post earnings of ($0.38) per share. Zacks’ earnings per share calculations are an average based on a survey of sell-side research firms that follow HTG Molecular Diagnostics.
HTG Molecular Diagnostics (NASDAQ:HTGM) last announced its earnings results on Thursday, March 7th. The medical research company reported ($0.07) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.20) by $0.13. The firm had revenue of $7.73 million during the quarter, compared to analysts’ expectations of $7.87 million. HTG Molecular Diagnostics had a negative return on equity of 64.49% and a negative net margin of 76.52%.
Several institutional investors and hedge funds have recently bought and sold shares of HTGM. Russell Investments Group Ltd. bought a new stake in shares of HTG Molecular Diagnostics in the third quarter valued at approximately $1,089,000. FMR LLC boosted its position in shares of HTG Molecular Diagnostics by 2.9% in the third quarter. FMR LLC now owns 3,588,045 shares of the medical research company’s stock valued at $18,120,000 after acquiring an additional 100,000 shares during the period. Virtu Financial LLC bought a new stake in shares of HTG Molecular Diagnostics in the third quarter valued at approximately $215,000. Symmetry Peak Management LLC bought a new stake in shares of HTG Molecular Diagnostics in the third quarter valued at approximately $429,000. Finally, Acadian Asset Management LLC boosted its position in shares of HTG Molecular Diagnostics by 152.3% in the fourth quarter. Acadian Asset Management LLC now owns 227,407 shares of the medical research company’s stock valued at $577,000 after acquiring an additional 137,276 shares during the period. 50.52% of the stock is owned by institutional investors.
Shares of HTG Molecular Diagnostics stock opened at $2.50 on Wednesday. The company has a debt-to-equity ratio of 0.32, a current ratio of 5.42 and a quick ratio of 5.23. HTG Molecular Diagnostics has a 12-month low of $2.03 and a 12-month high of $5.46.
HTG Molecular Diagnostics Company Profile
HTG Molecular Diagnostics, Inc develops and markets products and services based on proprietary technology that facilitates the routine use of targeted molecular profiling. The company offers instrumentation (or platforms); consumables comprising assay kits; and software analytics that automate sample processing and profiles various molecular targets.
Featured Story: Fiduciary
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for HTG Molecular Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HTG Molecular Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.